BACKGROUND: Cell senescence is a key process in age-associated dysfunction and diseases, notably chronic obstructive pulmonary disease (COPD). We previously identified phospholipase A2 receptor 1 (PLA2R1) as a positive regulator of cell senescence acting via Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signalling. Its role in pathology, however, remains unknown. Here, we assessed PLA2R1-induced senescence in COPD and lung emphysema pathogenesis. METHODS: We assessed cell senescence in lungs and cultured lung cells from patients with COPD and controls subjected to PLA2R1 knockdown, PLA2R1 gene transduction and treatment with the JAK1/2 inhibitor ruxolitinib. To assess whether PLA2R1 upregulation caused lung lesions, we developed transgenic mice overexpressing PLA2R1 (PLA2R1-TG) and intratracheally injected wild-type mice with a lentiviral vector carrying the Pla2r1 gene (LV-PLA2R1 mice). RESULTS: We found that PLA2R1 was overexpressed in various cell types exhibiting senescence characteristics in COPD lungs. PLA2R1 knockdown extended the population doubling capacity of these cells and inhibited their pro-inflammatory senescence-associated secretory phenotype (SASP). PLA2R1-mediated cell senescence in COPD was largely reversed by treatment with the potent JAK1/2 inhibitor ruxolitinib. Five-month-old PLA2R1-TG mice exhibited lung cell senescence, and developed lung emphysema and lung fibrosis together with pulmonary hypertension. Treatment with ruxolitinib induced reversal of lung emphysema and fibrosis. LV-PLA2R1-treated mice developed lung emphysema within 4 weeks and this was markedly attenuated by concomitant ruxolitinib treatment. CONCLUSIONS: Our data support a major role for PLA2R1 activation in driving lung cell senescence and lung alterations in COPD. Targeting JAK1/2 may represent a promising therapeutic approach for COPD.
- Beaulieu, D.
- Attwe, A.
- Breau, M.
- Lipskaia, L.
- Marcos, E.
- Born, E.
- Huang, J.
- Abid, S.
- Derumeaux, G.
- Houssaini, A.
- Maitre, B.
- Lefevre, M.
- Vienney, N.
- Bertolino, P.
- Jaber, S.
- Noureddine, H.
- Goehrig, D.
- Vindrieux, D.
- Bernard, D.
- Adnot, S.
Keywords
- Animals
- Cellular Senescence
- *Emphysema
- Humans
- Lung
- Mice
- *Pulmonary Disease, Chronic Obstructive/drug therapy
- *Pulmonary Emphysema
- Receptors, Phospholipase A2
- A. Attwe has nothing to disclose. Conflict of interest: M. Breau has nothing to
- disclose. Conflict of interest: L. Lipskaia has nothing to disclose. Conflict of
- interest: E. Marcos has nothing to disclose. Conflict of interest: E. Born has
- nothing to disclose. Conflict of interest: J. Huang has nothing to disclose.
- Conflict of interest: S. Abid has nothing to disclose. Conflict of interest: G.
- Derumeaux has nothing to disclose. Conflict of interest: A. Houssaini has nothing
- to disclose. Conflict of interest: B. Maitre has nothing to disclose. Conflict of
- interest: M. Lefevre has nothing to disclose. Conflict of interest: N. Vienney
- has nothing to disclose. Conflict of interest: P. Bertolino has nothing to
- disclose. Conflict of interest: S. Jaber has nothing to disclose. Conflict of
- interest: H. Noureddine has nothing to disclose. Conflict of interest: D. Goehrig
- has nothing to disclose. Conflict of interest: D. Vindrieux has nothing to
- disclose. Conflict of interest: D. Bernard has nothing to disclose. Conflict of
- interest: S. Adnot has nothing to disclose.